Oncology,
Health,
Medical Devices,
Technology,
Other Health,
Artificial Intelligence,
Biotechnology,
Patient,
Learning,
COTA,
Risk,
Baptist Health South Florida,
Recurrence,
Breast cancer,
MBA,
AI,
IBC,
Cancer,
Risk assessment,
Woman,
Artificial intelligence,
Baptist Health,
Physician,
Medical device Today, COTA, PreciseDx and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence (AI) -enabled PreciseBreast™ (PDxBr) test that predicts the likelihood of invasive breast cancer (IBC) recurrence.
Key Points:
- Today, COTA, PreciseDx and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence (AI) -enabled PreciseBreast™ (PDxBr) test that predicts the likelihood of invasive breast cancer (IBC) recurrence.
- One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime.
- Risk assessment to determine the likelihood of breast cancer recurrence is a critical step in characterizing a cancer diagnosis.
- While breast cancer patients have benefited from numerous gene-expression tests in recent years, these tools have documented limitations and can be expensive.
HER2,
Brain,
Algorithm,
Entrepreneurship,
Immunotherapy,
Disease,
Risk,
UCLA Health,
Patient,
Triple-negative breast cancer,
Neoplasm,
Research,
MD,
Medicine,
Hospital,
Breast cancer,
Risk assessment,
Pathology,
Prognosis,
Medical laboratory,
Recurrence,
TNBC,
UCLA,
Artificial intelligence,
Health,
Medical imaging NEW YORK, April 2, 2024 /PRNewswire/ -- PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis, today announced a sponsored research collaboration with UCLA's Department of Pathology and Laboratory Medicine in Los Angeles to evaluate PreciseBreast's™ ability to accurately assess risk of recurrence for patients with triple-negative breast cancer (TNBC). TNBC constitutes only 10-20% of all breast cancer cases, yet continues to demand significant clinical interest due to its limited response to conventional treatments, the association with younger women, BRCA1/2 mutations, ethnic/racial disparities, and its highly aggressive characteristics.
Key Points:
- Our collaboration with PreciseDx has the potential to greatly improve our approach to predicting and managing recurrence in TNBC patients, ultimately leading to enhanced outcomes."
- Integrating advanced AI algorithms and comprehensive clinical data, the collaborative study aims to confirm PreciseBreast as a highly effective and reliable digital breast cancer assay.
- This new assay will potentially enhance the early detection of TNBC recurrence and support personalized treatment strategies tailored to individual patient needs.
- The collaborative study between UCLA and PreciseDx represents a significant step forward in digital pathology and oncology breast cancer research.
Retrieved on:
Tuesday, November 7, 2023
Standard of care,
LDT,
New York State Department of Health,
Doctor of Philosophy,
Health,
Artificial intelligence,
CLIA,
Disease,
Risk,
Recurrence,
Machine learning,
IBC,
Breast cancer,
Histology,
NYSDOH,
Clinical Breast Cancer,
Breast Cancer Research,
Patient,
Medical device,
Medical imaging NEW YORK, Nov. 7, 2023 /PRNewswire/ -- PreciseDx®, a leading innovator in oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis, today announced that its analytical validation study for its PreciseBreast™ assessment has been published in the November 3, 2023 issue of Clinical Breast Cancer.
Key Points:
- Collectively, these studies demonstrated an analytical performance that accurately predicts early-stage breast cancer risk of recurrence within 6 years.
- PreciseBreast™ is an in vitro prognostic test that predicts breast cancer recurrence for patients diagnosed with early-stage IBC.
- This latest study builds upon PreciseDx's earlier clinical validation study published in Breast Cancer Research (cited 2022 Dec 21, 24:93.
- "Our innovative digital assessment holds immense promise in enhancing early-stage breast cancer recurrence prediction, ultimately improving patient care and outcomes.
Genomic Health,
Diehl,
IBM Watson,
Marie Cassidy,
Clinical trial,
Pathology,
Cancer,
Ted,
Strategic planning,
Patient,
Sanofi,
Growth,
AI,
Oncology,
Management,
Medical imaging NEW YORK, June 27, 2023 /PRNewswire/ -- PreciseDx, a leading innovator in AI-powered, patient-specific disease analysis, today announced the appointment of Ted M. Diehl as its new Vice President of Client Relations. With extensive leadership experience in the oncology diagnostic space, Diehl will play a pivotal role in driving commercial development, strategic planning, and sales leadership for the Company.
Key Points:
- NEW YORK, June 27, 2023 /PRNewswire/ -- PreciseDx , a leading innovator in AI-powered, patient-specific disease analysis, today announced the appointment of Ted M. Diehl as its new Vice President of Client Relations.
- "Ted is a valuable addition to our growing team," said Wayne Brinster, CEO of PreciseDx.
- "PreciseDx is delivering a new generation of pathology information and has distinguished itself as a leader in the field," said Diehl.
- I look forward to working with the talented team at PreciseDx to deploy its proven technology in healthcare settings globally."
Retrieved on:
Tuesday, February 21, 2023
Investment,
Master of Business Administration,
Harvard Business School,
Williams College,
Capital,
NY,
Milton Gendel,
Warburg Pincus,
Business administration,
Pathology,
Morgan Stanley,
Growth,
Financial management,
Bachelor of Arts,
NY State of Health,
Management NEW YORK, Feb. 21, 2023 /PRNewswire/ -- PreciseDx, a leading innovator in AI-powered, patient-specific disease analysis, today announced the appointment of Bradley Gendell as Chief Financial Officer. Joining the Company's leadership team, Gendell brings more than 30 years of financial management and growth experience, most recently as Managing Director of 3SPOKE Capital, a private investment firm focused on late-stage venture investments. In his role with PreciseDx, Gendell will be responsible for managing the growth and financial performance of the Company.
Key Points:
- NEW YORK, Feb. 21, 2023 /PRNewswire/ -- PreciseDx , a leading innovator in AI-powered, patient-specific disease analysis, today announced the appointment of Bradley Gendell as Chief Financial Officer.
- In his role with PreciseDx, Gendell will be responsible for managing the growth and financial performance of the Company.
- "Brad's background in operational and financial management and investment expertise is a welcomed asset to our team," said Wayne Brinster, CEO of PreciseDx.
- Gendell earned his Bachelor of Arts degree from Williams College, and holds a Masters in Business Administration from Harvard Business School.
Retrieved on:
Tuesday, February 7, 2023
CLEP,
LDT,
CLIA,
Breast cancer,
New York State Department of Health,
Patient,
Entrepreneurship,
Breast Cancer Research,
PDX,
Pathology,
NYSDOH,
Research,
AI,
Doctor of Philosophy,
Pharmaceutical industry,
Medical device,
Medical imaging NEW YORK, Feb. 7, 2023 /PRNewswire/ -- PreciseDx, a leading innovator in AI-powered, patient-specific disease analysis, today announced that the New York State Department of Health (NYSDOH) has approved the PDxBr, a Lab Developed Test (LDT) designed to enrich breast cancer grading and improve risk categorization. With this approval, PreciseDx can now begin commercially testing patient samples in the state of New York through its CLIA certified laboratory.
Key Points:
- With this approval, PreciseDx can now begin commercially testing patient samples in the state of New York through its CLIA certified laboratory.
- "We are pleased to receive the approval from the New York State Department of Health for our PDxBr breast test.
- The study detailed that the PDxBr breast test enriches breast cancer grading and improves risk categorization.
- "Now, with the recent approval from the New York State Department of Health, the testing platform will soon be available to providers and patients throughout the state."
Retrieved on:
Tuesday, January 31, 2023
Merative,
Paul Roma,
Broad Institute,
Artificial intelligence,
Mount Sinai Health System,
Francisco Partners,
Health,
MIT,
IBM,
Harvard University,
Insurance,
Growth,
Ciox Health,
Mayo Clinic,
Senior advisor,
AbbVie,
Research,
Management NEW YORK, Jan. 31, 2023 /PRNewswire/ -- PreciseDx, a leading innovator in AI-powered, patient-specific disease analysis, today announced the appointment of Paul Roma as Chairman of the Board of Directors. Roma brings decades of experience in corporate leadership and healthcare technology to PreciseDx as the company begins to expand its laboratory footprint and partnerships to make its PreciseDx Breast Test more available.
Key Points:
- Roma brings decades of experience in corporate leadership and healthcare technology to PreciseDx as the company begins to expand its laboratory footprint and partnerships to make its PreciseDx Breast Test more available.
- "We are delighted to have Paul join the PreciseDx board of directors as we work to positively impact patient outcomes through our technology and its ability to be accessed by anyone, anywhere," said Wayne Brinster, CEO of PreciseDx.
- "I am very excited to assume the role of Chairman of the PreciseDx Board of Directors and am pleased to work alongside the Company's expert leadership team," said Roma.
- "PreciseDx has shown tremendous potential in its ability to improve patient outcomes and healthcare through AI-powered, patient-specific risk information.
Retrieved on:
Tuesday, November 29, 2022
Pathology,
Machine learning,
Patient,
HER2,
Recurrence,
AI,
Doctor of Philosophy,
Hospital,
H&E,
Laboratory,
Oncology,
Breast cancer,
Algorithm,
Prognosis,
Histology,
Quality of life,
Intelligence,
Data set,
Marie Cassidy,
Survival,
Haematoxylin,
ER,
Medical device,
Medical imaging,
MD NEW YORK, Nov. 29, 2022 /PRNewswire/ -- PreciseDx, a leading AI company leveraging the analysis of morphology features from histology slides to provide more precise patient-specific risk information, today announced a collaboration with the Laboratory of Pathology at Dordrecht, Netherlands. The laboratory is responsible for the pathology of both the Albert Schweitzer Hospital in Dordrecht and the Beatrix Hospital in Gorinchem, both in the Netherlands. Through this agreement, the Laboratory of Pathology will study the performance of PreciseDx's AI-driven Cancer Risk Stratification platform, confirming its accuracy of staging and role in the decision process.
Key Points:
- The laboratory is responsible for the pathology of both the Albert Schweitzer Hospital in Dordrecht and the Beatrix Hospital in Gorinchem, both in the Netherlands.
- Finally, the collaboration will allow an evaluation of the PreciseDx assay within the context of current pathology workflow within Dr. Westenend laboratory practice," said Douglas P. Malinowski, Ph.D., Vice President of Clinical Affairs at PreciseDx.
- "The Laboratory of Pathology at Dordrecht and the affiliated hospitals share our forward-thinking, patient-centric approach to improving the long-term outlook and quality of life for patients with early-stage breast cancer.
- In addition, the collaboration will permit an assessment of the prognostic utility of the PreciseDx breast assay in comparison to other methods."
Retrieved on:
Wednesday, April 20, 2022
NEW YORK, April 20, 2022 /PRNewswire/ -- PreciseDx, recently spun out from the Mount Sinai Health System in New York, NY, is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features. The company today announced its AI-enabled digital pathology technology can accurately diagnose Parkinson's disease (PD) in living patients prior to severe onset of symptoms.
Key Points:
- The company today announced its AI-enabled digital pathology technology can accurately diagnose Parkinson's disease (PD) in living patients prior to severe onset of symptoms.
- Diagnosing Parkinson's disease is challenging at all stages due to variable symptoms, comorbidities, and mimicking conditions, with definitive diagnosis only coming postmortem.
- "Objective diagnostic tools, especially early in disease, are critical to drive care decisions and to design trials toward better treatments and cures."
- The AI edged out the human pathologist with an accuracy of 0.69 versus 0.64 in the prediction of clinical Parkinson's disease status.
Therapy,
Master of Business Administration,
Intelligence,
Technology,
University,
AbbVie,
Patient,
Harper,
Board of directors,
Catalyst Pharmaceuticals,
Cornell University,
UBS,
Wharton School of the University of Pennsylvania,
Lawrence Wilkerson,
Machine learning,
Lists of diseases,
Cave rescue,
Medicine,
Erasmus University Rotterdam,
Board,
Big data,
Business administration,
Union,
Company,
Leadership,
Research,
The Advisory Board Company,
Cancer,
CEO,
Converse,
Merck,
Synthetic biology,
Michigan State University,
Pathology,
Pharmaceutical industry,
Management,
Medical imaging,
Science,
Operation NEW YORK, March 15, 2022 /PRNewswire/ -- PreciseDx, the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, today announced the appointment of Molly Harper, Chief Business Officer for Synlogic, Inc., and Eric Converse, the Chief Executive Officer at AMRA Medical, to the Company's Board of Directors.
Key Points:
- "We could not be more pleased to have Molly and Eric join our team at PreciseDx and look forward to their continued contributions," said PreciseDx Chief Executive Officer, Wayne Brinster.
- Harper brings over 20 years of experience focusing on commercial strategy and leadership at life sciences companies of all sizes.
- Harper joined Synlogic, which brings the transformative potential of synthetic biology to medicine, from Relmada Therapeutics, Inc., where she was Executive Vice President of Operations.
- She also serves on the Board of Directors of Catalyst Pharmaceuticals, a commercial-stage biopharmaceutical company developing therapeutics for rare neurological diseases.
